351 related articles for article (PubMed ID: 35013850)
1. Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.
Rommasi F; Nasiri MJ; Mirsaeidi M
Mol Cell Biochem; 2022 Mar; 477(3):711-726. PubMed ID: 35013850
[TBL] [Abstract][Full Text] [Related]
2. Baricitinib set to join the Covid-19 therapeutic arsenal?
Gudu T; Stober C; Cope AP; Cheriyan J; Galloway J; Wilkinson IB; Kostapanos M; Jayne D; Hall F
Rheumatology (Oxford); 2021 Apr; 60(4):1585-1587. PubMed ID: 33502499
[No Abstract] [Full Text] [Related]
3. Immunopathogenesis and treatment of cytokine storm in COVID-19.
Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
5. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
Jorgensen SCJ; Tse CLY; Burry L; Dresser LD
Pharmacotherapy; 2020 Aug; 40(8):843-856. PubMed ID: 32542785
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
[TBL] [Abstract][Full Text] [Related]
7. The effect of drugs used in rheumatology for treating SARS-CoV2 infection.
Atzeni F; Gerratana E; Giallanza M; La Corte L; Nucera V; Miceli G; Sangari D; Masala IF
Expert Opin Biol Ther; 2021 Feb; 21(2):219-228. PubMed ID: 32866053
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice.
Sakai H; Kamuro H; Tokunoh N; Izawa T; Tamiya S; Yamamoto A; Tanaka S; Okuzaki D; Ono C; Matsuura Y; Okada Y; Yoshioka Y; Fujio Y; Obana M
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F931-F941. PubMed ID: 38634132
[TBL] [Abstract][Full Text] [Related]
9. Two new and effective food-extracted immunomodulatory agents exhibit anti-inflammatory response activity in the hACE2 acute lung injury murine model of COVID-19.
Liu S; Wang B; Chen T; Wang H; Liu J; Zhao X; Zhang Y
Front Immunol; 2024; 15():1374541. PubMed ID: 38807598
[TBL] [Abstract][Full Text] [Related]
10. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
11. COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods.
Marofi F; Azizi R; Motavalli R; Vahedi G; Nasimi M; Yousefi M; Motavalli Y; Tahmasebi S; Gharibi T; Mohammed RN; Etemadi J; Khiavi FM
Anticancer Agents Med Chem; 2021 Oct; 21(16):2142-2162. PubMed ID: 33563186
[TBL] [Abstract][Full Text] [Related]
12. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19.
Kumar R; Rathi H; Haq A; Wimalawansa SJ; Sharma A
Virus Res; 2021 Jan; 292():198235. PubMed ID: 33232783
[TBL] [Abstract][Full Text] [Related]
13. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
Elife; 2020 Apr; 9():. PubMed ID: 32338605
[TBL] [Abstract][Full Text] [Related]
14. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
Rohilla S
Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
[TBL] [Abstract][Full Text] [Related]
15. Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Yadav AK; Wen S; Xu X; Yu L
Ann Palliat Med; 2021 Jan; 10(1):707-720. PubMed ID: 33440983
[TBL] [Abstract][Full Text] [Related]
16. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
[TBL] [Abstract][Full Text] [Related]
17. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
Stebbing J; Sánchez Nievas G; Falcone M; Youhanna S; Richardson P; Ottaviani S; Shen JX; Sommerauer C; Tiseo G; Ghiadoni L; Virdis A; Monzani F; Rizos LR; Forfori F; Avendaño Céspedes A; De Marco S; Carrozzi L; Lena F; Sánchez-Jurado PM; Lacerenza LG; Cesira N; Caldevilla Bernardo D; Perrella A; Niccoli L; Méndez LS; Matarrese D; Goletti D; Tan YJ; Monteil V; Dranitsaris G; Cantini F; Farcomeni A; Dutta S; Burley SK; Zhang H; Pistello M; Li W; Romero MM; Andrés Pretel F; Simón-Talero RS; García-Molina R; Kutter C; Felce JH; Nizami ZF; Miklosi AG; Penninger JM; Menichetti F; Mirazimi A; Abizanda P; Lauschke VM
Sci Adv; 2021 Jan; 7(1):. PubMed ID: 33187978
[TBL] [Abstract][Full Text] [Related]
18. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
20. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y
Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]